Blog Cell Based Assays Drugs 
Drug Target Review
JULY 7, 2025
Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Conventional models often fail to predict cardiac side effects, especially with biologics.
PerkinElmer
SEPTEMBER 8, 2019
Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. Learn more about Cisbio here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Molecular Design
DECEMBER 31, 2023
BW2014 has been heavily cited in the drug discovery literature (it was cited as the first reference in the ACS assay interference editorial which I reviewed in K2017 ) despite providing nothing in the way of practical advice for dealing with nuisance behavior. Given that M2003 had been published over a decade previously.
PerkinElmer
JANUARY 7, 2020
Drug discovery is always evolving. From new processes to advanced technologies, excellence in drug discovery is the result of combining different approaches. Emerging and Resurrecting Technologies We’ve made huge strides in the drug discovery process, and it’s only getting better as we move forward.
The ChEMBL-og
OCTOBER 12, 2020
ChEMBL contains a broad range of binding, functional and ADMET type assays in formats ranging from in vitro single protein assays to anti proliferative cell-based assays. Some variation is expected, even for very similar assays, since these are often performed by different groups and institutes.
Molecular Design
JUNE 8, 2023
I’ll start the review of L2021 with annotation of the abstract: "Physicochemical descriptors commonly used to define ‘drug-likeness’ and ligand efficiency measures are assessed for their ability to differentiate marketed drugs from compounds reported to bind to their efficacious target or targets. [I
FDA Law Blog: Drug Discovery
FEBRUARY 2, 2023
Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. FDORA § 3209(a)(2).
Expert insights. Personalized for you.
52 
Let's personalize your content